Brown2020

THERASENSE AND HEALTH HERO NETWORK ANNOUNCE LICENSE AGREEMENT FOR DIABETES DATA MONITORING AND PATIENT MANAGEMENT

Alameda, Calif. and Mountain View, Calif. - November 21, 2002 - TheraSense, Inc. (Nasdaq: THER), a leader in blood glucose monitoring and maker of the popular, virtually pain-free FreeStyle™ blood glucose monitoring system, and Health Hero Network, Inc., the developer of award-winning technology solutions for health monitoring, today announced the signing of a license agreement.

Under the agreement, Health Hero Network has granted to TheraSense a co-exclusive license in the field of diabetes to Health Hero’s extensive patent portfolio relating to medical data monitoring and patient management. In addition, Health Hero has agreed to extend its Health Buddy® product line to include download capabilities compatible with TheraSense’s FreeStyle and FreeStyle Tracker™ glucose monitoring products.

“TheraSense is a leading innovator in making diabetes monitoring virtually pain-free and convenient for people with diabetes, and Health Hero Network excels at making health monitoring and management easier for patients and care providers. Our strategic relationship with TheraSense will enable us to create products and services that improve the lives of people with diabetes and the people who care for them,” said Steve Brown, CEO and President of Health Hero Network.

“This agreement supports TheraSense’s current FreeStyle blood glucose monitoring products as well as our strategy for providing exceptional communication services to the users of our future products such as our real-time continuous glucose monitoring system in development,” said Mark Lortz, TheraSense President and CEO.

About TheraSense
TheraSense develops, manufactures and sells easy to use glucose monitoring systems that dramatically reduce the pain of testing for people with diabetes. TheraSense began selling its first product, the FreeStyle blood glucose monitoring system, in June 2000. The FreeStyle system has wide distribution in the United States through national retailers including Walgreens, Wal-Mart, CVS, Eckerd and Rite Aid. In Canada and the United Kingdom, the FreeStyle system is distributed through wholly owned TheraSense subsidiaries. The FreeStyle system is distributed in various European countries by Disetronic Group, the leading provider of insulin pumps in Europe. In Japan, the FreeStyle system is distributed by Nipro Corporation, the Japanese market leader in dialysis and insulin pumps. The TheraSense headquarters and test strip manufacturing facility are located in Alameda, California. Visit us at http://www.therasense.com.

About Health Hero Network
Health Hero Network, Inc., founded in 1988 and headquartered in Mountain View, California, develops and licenses industry-leading technology solutions for health monitoring and management. The Health Hero technology platform offers Internet-enabled care management tools, multiple patient interfaces, and a secure environment for data communications. The Company’s product line includes Health Buddy®, Health Buddy® Web and other licensee devices for data collection and communications with patients, and iCare Desktop™, an Internet-based care management and research solution for healthcare professionals. Health Hero offers over a dozen standard health management programs delivering daily monitoring & education, and promoting positive behavioral change for better chronic care with lower costs to the healthcare system. Health Hero Network technology is protected by over 50 issued U.S. patents. For more information about Health Hero Network, visit http://www.healthhero.com.

Forward-Looking Statements
The foregoing contains statements regarding development of and development strategy for new products and services. These statements are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and actual results could differ materially. We undertake no obligation to update or revise any forward-looking statement. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to: substantial competition in the market for blood glucose monitoring products; risks related to failure to protect our intellectual property and litigation in which we may become involved; risks relating to development of innovative products; risks related to noncompliance with FDA regulations; and limited manufacturing experience and dependence on single third-party manufacturers.

Investors should also read the risk factors set forth in TheraSense’s Form 10-Q for the quarter ended September 30, 2002 and periodic reports filed with the Securities and Exchange Commission. The risk factors are also available on the Investor Relations portion of TheraSense’s website at http://www.therasense.com.